PALB2 and pancreatic neoplasm: Outcomes of treatment with PARP inhibitors in pancreatic cancer patients with BRCAness (ATM, BAP1, BARD1, BLM, BRIP1, CHEK2, FAM175A, FANCA, FANCC, NBN, PALB2, RAD50, RAD51, RAD51C, and RTEL1), pathogenic variants in genes associated with HRR deficiency, remain unclear [144].